BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 9822361)

  • 1. p53 tumor suppressor protein and H-RAS oncogene in maxillofacial tumors: immunohistochemical and genetic investigation, induction chemotherapy response and prognosis evaluation.
    Cutilli T; Papola F; Di Emidio P; Corbacelli A
    J Chemother; 1998 Oct; 10(5):411-7. PubMed ID: 9822361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [p53 mutations and chemoresistance in oromaxillofacial squamous-cell carcinomas. The results of a molecular genetics study of p53 in metastatic oromaxillofacial tumors and an evaluation of the response to neoadjuvant chemotherapeutic treatment].
    Cutilli T; Papola F; Di Emidio P; Leocata P; Corbacelli A
    Minerva Stomatol; 1998; 47(1-2):1-9. PubMed ID: 9578641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma.
    Perrone F; Bossi P; Cortelazzi B; Locati L; Quattrone P; Pierotti MA; Pilotti S; Licitra L
    J Clin Oncol; 2010 Feb; 28(5):761-6. PubMed ID: 20048189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of p53 and apoptosis of tumor cells in locally advanced cervical carcinoma after cisplatin based neoadjuvant chemotherapy.
    Garzetti GG; Ciavattini A; Provinciali M; Di Stefano G; Lucarini G; Goteri G; Biagini G
    Anticancer Res; 1996; 16(5B):3229-34. PubMed ID: 8920796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study.
    Kandioler D; Schoppmann SF; Zwrtek R; Kappel S; Wolf B; Mittlböck M; Kührer I; Hejna M; Pluschnig U; Ba-Ssalamah A; Wrba F; Zacherl J
    J Thorac Cardiovasc Surg; 2014 Nov; 148(5):2280-6. PubMed ID: 25135238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of p53 protein as a prognostic factor for oral cancer surgery.
    Cutilli T; Leocata P; Dolo V; Altobelli E
    Br J Oral Maxillofac Surg; 2013 Dec; 51(8):922-7. PubMed ID: 23791033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer.
    Shiga H; Heath EI; Rasmussen AA; Trock B; Johnston PG; Forastiere AA; Langmacher M; Baylor A; Lee M; Cullen KJ
    Clin Cancer Res; 1999 Dec; 5(12):4097-104. PubMed ID: 10632346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 overexpression and mutation, chemoresistance and patient survival in oral and maxillofacial squamous cell carcinoma.
    Cutilli T; Papola F; Corbacelli A
    J Chemother; 1997 Apr; 9(2):123-4. PubMed ID: 9176754
    [No Abstract]   [Full Text] [Related]  

  • 9. Functional p53 status as a biomarker for chemotherapy response in oral-cavity cancer.
    Mroz EA; Rocco JW
    J Clin Oncol; 2010 Feb; 28(5):715-7. PubMed ID: 20048171
    [No Abstract]   [Full Text] [Related]  

  • 10. Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin.
    Yamamoto Y; Yamai H; Seike J; Yoshida T; Takechi H; Furukita Y; Kajiura K; Minato T; Bando Y; Tangoku A
    Ann Surg Oncol; 2012 Mar; 19(3):757-65. PubMed ID: 21947696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 genotype predicts response to chemotherapy in patients with squamous cell carcinoma of the esophagus.
    Yamasaki M; Miyata H; Fujiwara Y; Takiguchi S; Nakajima K; Nishida T; Yasuda T; Matsuyama J; Mori M; Doki Y
    Ann Surg Oncol; 2010 Feb; 17(2):634-42. PubMed ID: 19941080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 Mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer.
    Makino T; Yamasaki M; Miyata H; Yoshioka S; Takiguchi S; Fujiwara Y; Nakajima K; Nishida T; Mori M; Doki Y
    Ann Surg Oncol; 2010 Mar; 17(3):804-11. PubMed ID: 19885698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expression of oncogenes C-myc, C-raf and N-ras in advanced cancers of the upper respiratory and digestive tracts. Correlation with tumor clinical response to chemotherapy].
    Reyt E; Lavieille JP; Brambilla E; Barra Y; Riva C
    Ann Otolaryngol Chir Cervicofac; 1993; 110(6):310-5. PubMed ID: 8210089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of pre-chemotherapy hemoglobin and platelet levels in patients with stage Ib2-IIb cervical cancer treated with neoadjuvant chemotherapy followed by radical hysterectomy].
    Wang D; Wu M; Ren T; Wan XR; Feng FZ; Huang HF; Yang JX; Shen K; Xiang Y
    Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):577-81. PubMed ID: 23141176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemotherapy in squamous cell carcinoma of the esophagus using low dose continuous infusion 5-fluorouracil and cisplatin: results of a prospective study.
    Aroori S; Parshad R; Kapoor A; Gupta SD; Kumar A; Chattophadyay TK
    Indian J Cancer; 2004; 41(1):3-7. PubMed ID: 15105572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of response to chemo-radiotherapy and radiotherapy for esophageal squamous cell carcinoma.
    Miyazaki T; Kato H; Faried A; Sohda M; Nakajima M; Fukai Y; Masuda N; Manda R; Fukuchi M; Ojima H; Tsukada K; Kuwano H
    Anticancer Res; 2005; 25(4):2749-55. PubMed ID: 16080521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 expression in locally advanced pharyngeal squamous cell carcinoma.
    Lassaletta L; Brandáriz JA; Benito A; de la Cruz J; Gómez C; Ballestín C; Hitt R; Colomer R; Alvarez-Vicent JJ
    Arch Otolaryngol Head Neck Surg; 1999 Dec; 125(12):1356-9. PubMed ID: 10604414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour stage, node stage, p53 gene status, and bcl-2 protein expression as predictors of tumour response to platin-fluorouracil chemotherapy in patients with squamous-cell carcinoma of the head and neck.
    Fouret P; Temam S; Charlotte F; Lacau-St-Guily J
    Br J Cancer; 2002 Dec; 87(12):1390-5. PubMed ID: 12454767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series.
    Cabelguenne A; Blons H; de Waziers I; Carnot F; Houllier AM; Soussi T; Brasnu D; Beaune P; Laccourreye O; Laurent-Puig P
    J Clin Oncol; 2000 Apr; 18(7):1465-73. PubMed ID: 10735894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A preliminary experience of chemotherapy using cisplatin (CDDP) in oral and maxillofacial carcinoma].
    Qiu WL
    Zhonghua Kou Qiang Yi Xue Za Zhi; 1989 Mar; 24(2):69-71, 127. PubMed ID: 2480209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.